Skip to content

Clinical trials

Leukemia, Myeloid, Acute trials in South Korea

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Country / region: South Korea Clear all

114 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20031
20043
20061
20072
20081
20094
20106
20115
20121
20138
20143
20158
20168
201713
20188
20195
20209
20217
20224
20234
20242
20255
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed54
Terminated20
Unknown status15
Recruiting13
Active, not recruiting9
Enrolling by invitation2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Asan Medical Center12
Novartis Pharmaceuticals10
AbbVie9
Cooperative Study Group A for Hematology5
Astellas Pharma Global Development, Inc.4
Celgene4
Daiichi Sankyo4
Janssen Research & Development, LLC4
Samsung Medical Center4
Astex Pharmaceuticals, Inc.3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute114
Myelodysplastic Syndromes22
Leukemia17
Leukemia, Myelomonocytic, Chronic14
Recurrence12
Precursor Cell Lymphoblastic Leukemia-Lymphoma11
Multiple Myeloma10
Lymphoma, Non-Hodgkin9
Neoplasms9
Leukemia, Lymphocytic, Chronic, B-Cell8

Trials

Showing 1 to 25 of 114. Each trial links to its page on Pharma Observatory.

14 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.